Skip to main content

Table 1 Distribution of demographic/clinical traits by site and summary of PSQI scores

From: Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer

1A

 

All Patients

Inpatients

Outpatients

Site Effect

Demographic/Clinical

(n = 84)

(n = 42)

(n = 42)

(χ 2 , p) a

Age in years

(Mean; Range)

62 (40-94)

57(40-78)

66(47-94)

4.0, <0.01

Sex (M:F)b

65:19

23:19

42:00:00

24.6, <0.01

Cancer Stage

(IIB:IIIA&B: IV)b

1:18:65

0:10:32

1:08:33

NS

Prior Therapy (Yes:No)b

31:52

21:20

10:32

NS

WHO ECOG (0:1:2)b

30:42:11

17:18:07

13:24:04

NS

COPD (No: Mild: Mod: Severe)

ND

ND

14:7:13:8

ND

1B

 

All Patients

Inpatients

Outpatients

Site Effect

PSQI Sleep Factor

(n = 64)

(n = 37)

(n = 35)

(t, p ) a

Sleep Quality

1.40 ± 0.11

1.23 ± 0.14

1.56 ± 0.16

NS

Sleep Latency

1.48 ± 0.12

1.46 ± 0.16

1.50 ± 0.18

NS

Sleep Duration

1.63 ± 0.14

1.62 ± 0.20

1.63 ± 0.20

NS

Sleep Efficiency

1.65 ± 0.16

1.57 ± 0.23

1.74 ± 0.21

NS

Sleep Disturbance

2.11 ± 0.12

1.80 ± 0.17

2.30 ± 0.15

5.6, 0.02

Sleep Medication

0.78 ± 0.12

0.81 ± 0.17

0.75 ± 0.17

NS

Daytime Dysfunction

1.34 ± 0.13

1.16 ± 0.16

1.52 ± 0.20

NS

Global Sleep Quality Score

11.19 ± 0.66

10.86 ± 0.93

11.54 ± 0.94

NS

  1. a Based on t-test (t, p-value). b Values are numbers of patients. c Owen et al (1999) 26, 1649-51; NS = not significant; ND = no data available
  2. a Based on t-test (t, p-value)